Drug Trial Radar · NCT03386721
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
256
Actual
Start
Feb 19, 2018
Primary completion
Dec 30, 2021
Study completion Dec 30, 2021
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor activity of simlukafusp alfa in combination with atezolizumab in participants with advanced and/or metastatic solid tumors. Currently the focus is on participants with Head and Neck, oesophageal and cervical cancers with confirmed squamous cell carcinoma histology type.
Conditions
- Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Interventions
simlukafusp alfaDrug
simlukafusp alfa will be administered as per the dosage regimen mentioned in arm descriptions.
Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 AntibodyDrug
Atezolizumab will be administered as per the dosage regimen mentioned in arm descriptions.
GemcitabineDrug
Single-agent treatment administered as per approved protocol.
VinorelbineDrug
Single-agent treatment administered as per approved protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Baseline up to disease progression or study treatment discontinuation (up to 38 months)
Locations
44 sites in 15 countries. Site status is shown where the registry gives one.
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Cancer Treatment Centers of America
Newnan, Georgia
UZ Antwerpen
Edegem, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Institut Bergonie
Bordeaux, France
Hopital Timone Adultes; Oncologie Medicale Et Usp
Marseille, France
ICM; Medecine B3
Montpellier, France
Gustave Roussy Cancer Campus
Villejuif, France
Universitätsklinikum Essen; Innere Klinik (Tumorforschung)
Essen, Germany
Rambam Medical Center; Oncology
Haifa, Israel
Auckland City Hospital; Clinical Oncology
Auckland, New Zealand
Uniwersyteckie Centrum Kliniczne; Osrodek Badan Wczesnych Faz
Gda?sk, Poland
Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz
Warsaw, Poland
N.N.Burdenko Main Military Clinical Hospital; Oncology Dept
Moscow, Russia
S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
Saint Petersburg, Russia
National University Hospital; National University Cancer Institute, Singapore (NCIS)
Singapore, Singapore
National Cancer Centre; Medical Oncology
Singapore, Singapore
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital del Mar; Servicio de Oncologia
Barcelona, Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Barcelona, Spain
Clinica Universidad de Navarra Madrid; Servicio de Oncología
Madrid, Spain
Hospital Ramon y Cajal; Servicio de Oncologia
Madrid, Spain
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, Spain
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC
Madrid, Spain
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
Valencia, Spain
Clinica Universitaria de Navarra
Pamplona, Navarre, Spain
Hôpitaux Universit. de Genève Médecine Oncologie; Oncologie
Geneva, Switzerland
National Cheng Kung Uni Hospital; Dept of Hematology and Oncology
Tainan, Taiwan
National Taiwan Uni Hospital; Dept of Oncology
Taipei, Taiwan
Adana Baskent University Hospital; Medical Oncology
Adana, Turkey (Türkiye)
Akdeniz University Medical Faculty; Medical Oncology Department
Antalya, Turkey (Türkiye)
Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi
Edirne, Turkey (Türkiye)
Istanbul University Cerrahpa?a-Cerrahpa?a Medical Faculty; Medikal Onkoloji Departmani
Istanbul, Turkey (Türkiye)
?zmir Medical Park; Onkoloji
Izmir, Turkey (Türkiye)
Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
Kadiköy, Turkey (Türkiye)
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.